Functional Polymorphisms and Gene Expression of TLR9 Gene as Protective Factors for Nasopharyngeal Carcinoma Severity and Progression
Table 4
Univariate and multivariate Cox proportional hazards model for prognostic significance of pathologic features and TLR9 promoter polymorphisms on overall survival (OVS), distant metastases-free survival (DMFS), and locoregional recurrence-free survival (LRRFS).
Overall survival (OVS)
Distant metastases-free survival (DMFS)
Locoregional recurrence-free survival (LRRFS)
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
HR
95% CI
value
HR
95% CI
value
HR
95% CI
value
HR
95% CI
value
HR
95% CI
value
HR
95% CI
value
Agea
4.622
1.80-11.83
0.001
4.05
1.57-10.4
0.004
2.540
1.22-5.28
0.013
ni
2.816
1.35-5.84
0.005
2.716
1.30-5.65
0.008
Sexb
2.322
1.06-5.05
0.034
ni
3.134
1.39-7.02
0.006
2.855
1.19-6.84
0.019
2.496
1.20-5.17
0.014
ni
Tumor sizec
0.657
0.35-1.23
0.190
ni
0.739
0.41-1.32
0.310
ni
0.991
0.55-1.78
0.979
ni
Lymph noded
0.965
0.48-1.94
0.920
ni
1.269
0.26-2.56
0.507
ni
1.378
0.68-2.77
0.370
ni
Metastasise
3.708
1.44-9.54
0.007
3.35
1.29-8.69
0.013
5.264
2.42-11.42
0.00002
5.016
1.19-6.84
0.00007
1.130
0.27-4.67
0.866
ni
Clinical stagef
0.910
0.323-2.56
0.858
ni
1.376
0.426-4.44
0.593
ni
1.496
0.46-4.82
0.500
ni
TLR9-1486 T/Cg
1.416
0.70-2.84
0.328
ns
1.308
0.68-2.50
0.417
ns
1.365
0.71-2.60
0.344
ns
TLR9-1237 T/Ch
0.215
0.06-0.697
0.010
0.244
0.75-0.798
0.02
0.414
0.17-0.98
0.045
0.388
0.15-1.00
0.048
0.468
0.20-1.04
0.065
0.507
0.22-1.13
0.099
HR: hazard ratio; ni: not included in multivariate analysis; ns: nonsignificant; a: ≤35 versus >35 years; b: men versus women; c: T1-T2 versus T3-T4; d: N0 versus N+; e: M0 versus M+; f: I–II versus III-IV; g, h: TT versus TC+CC.
